Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

David Cragg Biography and Net Worth

Insider of Cytokinetics

Dave has led our Human Resources department since he joined us in February 2005. Dave was promoted to SVP in 2009 and to Chief Human Resources and Administration Officer in March 2019.

Prior to joining Cytokinetics, Dave managed his own human resources consulting practice, assisting organizations with building human resources infrastructure. During his extensive HR career, Dave held HR leadership roles with a number of biotechnology and high technology companies, including eGroups Inc. (acquired by Yahoo! Inc.), Genentech, Inc., Software Publishing Corporation, West Marine, Inc., and LSI Logic Corporation.

Mr. Cragg holds a B.A. in Industrial Psychology from the University of California, Santa Cruz.

Dave keeps busy in his personal time as an avid car enthusiast with several classic cars, vintage hifi equipment and canoeing. He also serves on the ALSA Golden West Chapter Board of Directors.

How do I contact David W. Cragg?: The corporate mailing address for Mr. Cragg and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on David W. Cragg's contact information.
Has David W. Cragg been buying or selling shares of Cytokinetics?: David W. Cragg has not been actively trading shares of Cytokinetics within the last three months. Most recently, David Cragg sold 45,000 shares of the business's stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $41.76, for a transaction totalling $1,879,200.00. Learn More on David W. Cragg's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 43 times. They sold a total of 432,011 shares worth more than $27,490,574.11. The most recent insider tranaction occured on November, 18th when CEO Robert I Blum sold 5,000 shares worth more than $252,750.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 11/18/2024.

David W. Cragg Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/9/2021	Sell	45,000	$41.76	$1,879,200.00
11/1/2021	Sell	25,000	$34.89	$872,250.00
10/1/2021	Sell	7,569	$35.14	$265,974.66
8/2/2021	Sell	2,616	$29.67	$77,616.72
6/1/2021	Sell	14,999	$21.63	$324,428.37

David W. Cragg Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $49.86

$49.65

$50.95

50 Day Range

MA: $53.86

$49.86

$58.62

2 Week Range

Now: $49.86

$30.68

$110.25

Volume

1,063,163 shs

Average Volume

1,256,900 shs

Market Capitalization

$5.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

This company will win the AI race

From Porter & Company | Ad